I propose to take Questions Nos. 175 to 179, inclusive, together.
The health boards have completed the examination of their immunisation records in relation to the extent to which Trivax three-in-one vaccine from certain lots produced from batch no. 3741 was used in the period 1968-70.
The health boards have identified a total of 295 records relating to children who received vaccine from three of the lot numbers concerned. Of these, 183 were in the Mid-Western Health Board area, 109 in the Southern Health Board area and three in the Western Health Board area.
My Department is considering the health boards' responses with a view to determining what, if any, further action is appropriate in this matter.
Glaxo Wellcome Limited, the successor to the company which produced the Trivax vaccine, has indicated to my Department that a variety of tests were used to analyse Trivax in the late 1960s and that all batches of Trivax released for sale complied with the mandatory requirements at that time. The company added that the results of all tests, mandatory and otherwise, together with expert advice which the company had sought, indicate that no other batch gave rise to the same level of potential concern as batch 3741.